

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Ali-Jackson Kamil</u> (Last) (First) (Middle) <u>C/O ACLARIS THERAPEUTICS, INC.</u> <u>640 LEE ROAD, SUITE 200</u> (Street) <u>WAYNE PA 19087</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Aclaris Therapeutics, Inc. [ACRS]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Legal Officer</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>01/03/2022</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/03/2022		M		3,875	A	(1)	118,571	D	
Common Stock	01/03/2022		M		27,905	A	(1)	146,476	D	
Common Stock	01/03/2022		M		6,638	A	(1)	153,114	D	
Common Stock	01/03/2022		M		7,100	A	(1)	160,214	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Restricted Stock Units	(1)	01/03/2022		M			3,875 ⁽²⁾	(3)	(3)	Common Stock	3,875	\$0.00	0	D	
Restricted Stock Units	(1)	01/03/2022		M			27,905 ⁽²⁾	(4)	(4)	Common Stock	34,350	\$0.00	0	D	
Restricted Stock Unit	(1)	01/03/2022		M			6,638 ⁽²⁾	(5)	(5)	Common Stock	19,914	\$0.00	0	D	
Restricted Stock Units	(1)	01/03/2022		M			7,100 ⁽²⁾	(6)	(6)	Common Stock	28,400	\$0.00	0	D	

Explanation of Responses:

- Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
- Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited.
- The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
- The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
- The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
- The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.

Remarks:

/s/ Mark Ballantyne, Attorney-in-Fact 01/05/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.